HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.

Abstract
It is an important challenge to better understand the mechanisms of tyrosine kinase inhibitors-induced apoptosis in CML cells. Thus, we have investigated how this apoptosis can be modulated by extracellular factors. Apoptosis induced by imatinib and nilotinib was determined in BCR-ABL expressing cell lines and primary CML CD34+ cells. Both molecules induced apoptosis of BCR-ABL expressing cells. This apoptosis was inhibited by protein synthesis inhibition in both K562 and CML CD34+ cells. In K562, 80% inhibition of the BCR-ABL auto-phosphorylation by either imatinib or nilotinib induced a two fold increase in Bim-EL expression and induction of apoptosis in 48 h. Bim accumulation preceded apoptosis induction which was completely abolished by depletion in Bim using shRNA. However, the anti-proliferative effect of imatinib was preserved in Bim-depleted cells. When K562 cells were cultured in a cytokine containing medium, the pro-apoptotic effect of nilotinib was decreased by 68% and this was related to a decrease in Bim-EL dephosphorylation and accumulation. Similarly, the presence of a combination of cytokines inhibited 88% of NIL- and 39% of IMA-induced apoptosis in primary CML CD34+ cells. In conclusion, both nilotinib and imatinib induce apoptosis through Bim accumulation independently of cell cycle arrest. However, the pro-apoptotic effect of both molecules can be attenuated by the presence of cytokines and growth factors, particularly concerning nilotinib. Thus BCR-ABL inhibition restores the cytokine dependence but is not sufficient to induce apoptosis when other signaling pathways are activated.
AuthorsFrancis Belloc, François Moreau-Gaudry, Maialen Uhalde, Laurie Cazalis, Marie Jeanneteau, Francis Lacombe, Vincent Praloran, François-Xavier Mahon
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 6 Issue 6 Pg. 912-9 (Jun 2007) ISSN: 1555-8576 [Electronic] United States
PMID17538248 (Publication Type: Journal Article)
Chemical References
  • Antigens, CD34
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • BCL2L11 protein, human
  • Bcl-2-Like Protein 11
  • Bcl2l11 protein, mouse
  • Benzamides
  • Cytokines
  • Membrane Proteins
  • Piperazines
  • Proto-Oncogene Proteins
  • Pyrimidines
  • Imatinib Mesylate
  • nilotinib
Topics
  • Animals
  • Antigens, CD34 (biosynthesis)
  • Antineoplastic Agents (pharmacology)
  • Apoptosis
  • Apoptosis Regulatory Proteins (metabolism)
  • Bcl-2-Like Protein 11
  • Benzamides
  • Cell Line, Tumor
  • Cytokines (metabolism)
  • Gene Expression Regulation, Leukemic
  • Humans
  • Imatinib Mesylate
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
  • Membrane Proteins (metabolism)
  • Mice
  • Models, Biological
  • Piperazines (pharmacology)
  • Proto-Oncogene Proteins (metabolism)
  • Pyrimidines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: